NEW YORK (GenomeWeb) – Metamark Genetics said today that it has signed a deal to become the exclusive worldwide sales agent for Hologic's Progensa PCA3 prostate cancer assay. The companies have also agreed to collaborate on a second-generation version of the test.

The Progensa test is designed to measure overexpression of prostate cancer antigen 3 (PCA3) RNA in urine samples and was cleared by the US Food and Drug Administration in 2012 for use on Hologic's semi-automated DTS system.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.